NEW YORK (GenomeWeb News) – Agilent Technologies said today that French biotech firm Imaxio has achieved Certified Service Provider status for the SureSelect Target Enrichment System for next-generation sequencing.

Imaxio was already a CSP for Agilent's microarray services and participated in comprehensive on-site training and passed a set of requirements demonstrating expertise and skill to receive CSP status for the SureSelect system, Agilent said. SureSelect is compatible with major NGS platforms, such as Illumina, Life Technologies' SOLiD, and Roche's 454.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.